Overview of percentage of positive functional Pgp in AML
| Authors . | No. of patients . | Median age, y (range) . | Type of AML . | Probe(s)/modulator . | Positive patients, % . |
|---|---|---|---|---|---|
| Lamy et al (1995)33 | 60 | 52 (18-75) | De novo AML | Rhodamine 123/verapamil | 50 |
| Leith et al (1997)30 | 175 | 68 (56-88) | De novo and secondary AML | Di(OC)2/CsA | 58 |
| Borg et al (1998)34 | 91 | 53 (16-75) | 70 de novo AML, 21 secondary AML | Rhodamine 123/PSC 833 | 26 |
| Pallis et al (1999)35 | 47 | 55 (16-77) | AML | Rhodamine 123/CsA | 40 |
| Legrand et al (1999)15 | 80 | 54 (17-80) | 60 de novo AML, 20 relapse AML | Calcein-AM/CsA | 32 |
| Leith et al (1999)14 | 318 | 44 (17-69) | De novo AML | Di(OC)2 and Rho123/CsA | 41 |
| Legrand et al (current study) | 129 | 58 (16-75) | De novo AML | JC-1/CsA | 65 |
| Authors . | No. of patients . | Median age, y (range) . | Type of AML . | Probe(s)/modulator . | Positive patients, % . |
|---|---|---|---|---|---|
| Lamy et al (1995)33 | 60 | 52 (18-75) | De novo AML | Rhodamine 123/verapamil | 50 |
| Leith et al (1997)30 | 175 | 68 (56-88) | De novo and secondary AML | Di(OC)2/CsA | 58 |
| Borg et al (1998)34 | 91 | 53 (16-75) | 70 de novo AML, 21 secondary AML | Rhodamine 123/PSC 833 | 26 |
| Pallis et al (1999)35 | 47 | 55 (16-77) | AML | Rhodamine 123/CsA | 40 |
| Legrand et al (1999)15 | 80 | 54 (17-80) | 60 de novo AML, 20 relapse AML | Calcein-AM/CsA | 32 |
| Leith et al (1999)14 | 318 | 44 (17-69) | De novo AML | Di(OC)2 and Rho123/CsA | 41 |
| Legrand et al (current study) | 129 | 58 (16-75) | De novo AML | JC-1/CsA | 65 |